GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenyn Biotechnology Co Ltd (ROCO:6846) » Definitions » Equity-to-Asset

Greenyn Biotechnology Co (ROCO:6846) Equity-to-Asset : 0.61 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Greenyn Biotechnology Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Greenyn Biotechnology Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was NT$745.6 Mil. Greenyn Biotechnology Co's Total Assets for the quarter that ended in Mar. 2024 was NT$1,215.4 Mil. Therefore, Greenyn Biotechnology Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.61.

The historical rank and industry rank for Greenyn Biotechnology Co's Equity-to-Asset or its related term are showing as below:

ROCO:6846' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.57   Med: 0.67   Max: 0.75
Current: 0.61

During the past 5 years, the highest Equity to Asset Ratio of Greenyn Biotechnology Co was 0.75. The lowest was 0.57. And the median was 0.67.

ROCO:6846's Equity-to-Asset is ranked better than
52.97% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs ROCO:6846: 0.61

Greenyn Biotechnology Co Equity-to-Asset Historical Data

The historical data trend for Greenyn Biotechnology Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenyn Biotechnology Co Equity-to-Asset Chart

Greenyn Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
0.61 0.66 0.73 0.67 0.69

Greenyn Biotechnology Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.72 0.75 0.69 0.61

Competitive Comparison of Greenyn Biotechnology Co's Equity-to-Asset

For the Biotechnology subindustry, Greenyn Biotechnology Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Greenyn Biotechnology Co's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenyn Biotechnology Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Greenyn Biotechnology Co's Equity-to-Asset falls into.



Greenyn Biotechnology Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Greenyn Biotechnology Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=796.911/1161.387
=0.69

Greenyn Biotechnology Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=745.59/1215.408
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Greenyn Biotechnology Co  (ROCO:6846) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Greenyn Biotechnology Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Greenyn Biotechnology Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Greenyn Biotechnology Co (ROCO:6846) Business Description

Traded in Other Exchanges
N/A
Address
5th Floor, No 43 Keya Road, Daya District, Taichung, TWN
Greenyn Biotechnology Co Ltd has developed Insumate patented sequenced peptide, Antromax Antrodia cinnamomea mycelia, and Zymologist fermented liquid.

Greenyn Biotechnology Co (ROCO:6846) Headlines

No Headlines